A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

Inclusion Criteria: * Were currently receiving an analgesic regimen that contained gabapentin * Had been on a stable dose of gabapentin for at least 14 days (same dose ±10% for 14 days) * Had a partial response to a gabapentin-containing analgesic regimen defined as an average daily pain intensity score of \>4 on a ) to 10 scale, with 0 being no pain and 10 being pain as bas as the patients have ever imagined (Question 5 of the Brief Pain Inventory \[BPI\] within 24 hours prior to the screening visit * For diabetic patients, had a hemoglobin A1c level \<0.13 (normal range, 0.047-0.064) Exclusion Criteria: * Had a neurological condition other than that associated with their pain diagnosis that, in the opinion of the investigator, would have interfered with their ability to participate in the study * Had received an epidural steroid/local anesthetic injection within 14 days prior to study entry * Had received trigger point injections within 14 days prior to study entry * Had received Botox injections within 3 months prior to study entry * Were taking a lidocaine-containing product that could not be discontinued while receiving Lidoderm * Were taking Class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)